






**A**



**B**



**C**



**FIG. 1**

BEST AVAILABLE COPY

2/5

	1	10	20	30	40	50
HUMAN	MAAMD	DVDP	.....	SGTNSGAG	KKRFE	VKNNAVALMAWDI
MOUSE	MAAMD	DVDP	.....	SGTNSGAG	KKRFE	VKNNAVALMAWDI
DROS	MEVDE	DGYEV	.....	PSSSSKGD	KKRFE	VKNNAVALMAWDI
ELEGANS	MAQAS	DSTAMEV	.....	EEATNQ	TVKKRFE	VKNNAVALMAWDI
YEAST	MSNEVD	DRMDVDE	DESQNI	AQSSNQ	SAPVET	TKKKRFE
APC11	M.....	.....	.....	.....	KVKINEV	HSVFAWSWHT
		60	70	80	90	100
HUMAN	LCIEC	QANQ	ASATSE	EC	TVAWG	VCNNAHAF
MOUSE	LCIEC	QANQ	ASATSE	EC	TVAWG	VCNNAHAF
DROS	LCIEC	QANQ	ASATSE	EC	TVAWG	VCNNAHAF
ELEGANS	LCIEC	QANQ	ASATSE	EC	TVAWG	VCNNAHAF
YEAST	PCIEC	QPKAM	TDTDNEC	VAAWG	VCNNAHAF	HLHCIN
APC11	TCPS	CKFP	G.....	DQC	PLVIG	ICLCHN

60aa



FIG. 2









FIG. 3

# A

<b><i>rbx1</i>Δ</b>	<b>inviable</b>
<b><i>rbx1</i>Δ / pGAL-mRbx1 (WT)</b>	<b>viable</b>
<b><i>rbx1</i>Δ / pGAL-mrbx1 (M3)</b>	<b>inviable</b>
<b><i>rbx1</i>Δ / pGAL-mrbx1 (M4)</b>	<b>viable</b>



# B



C




FIG. 4

BEST AVAILABLE COPY

5/5




FIG. 5

